Close Window

Digital Look Email A Friend

GSK reports more encouraging trial results for Blenrep

Published by Josh White on 7th March 2024

(Sharecast News) - GSK unveiled encouraging results from its 'DREAMM-8' phase three trial on Thursday, comparing the efficacy of 'Blenrep', or belantamab mafodotin, in combination with pomalidomide plus dexamethasone, or PomDex, against the standard treatment of bortezomib plus PomDex in relapsed or refractory multiple myeloma patients.

URL: http://www.digitallook.com/dl/news/story/34138948/...

Email this article to your friends
NOTE: These email addresses will be used to email the information on your behalf and will not be collected by Digital Look for any marketing purposes.